Speakers
Elsa Abranches, Chief Scientific Officer, ViSync Technologies
Amina Al-Mossawi, Qualified Person, MeiraGTx
Nicola Ambler, Founder, The CGT Circle
Peter Andersen, Chief Research & Development Officer, Treefrog Therapeutics
Catia Andreassi, Director, Aviadobio
Marta Arrizabalaga Cascallana, PhD Researcher, UCL
Owen Bain, Director, Centre for Cell Gene Tissue Therapeutics, Royal Free NHS Trust
Chris Baldwin, Vice President, Manufacturing & Supply, Resolution Therapeutics
Ricardo Baptista, Chief Technology Officer, Smartcella
Ivana Barbaric, Professor of Stem Cell Biology, The University of Sheffield
Samantha Barber, Chief Executive Officer, Gene People
Kate Barclay, Skills Strategy Consultant, UK Bioindustry Association
Mark Battaglini, Chief Strategy Officer, Alliance for Regenerative Medicine
Cecile Bauche, Chief Scientific Officer, Alaya.bio
Cornelia Baumgartner, Clinical Operations Manager, T-CURX GmbH
Roy Baynes, Executive Vice President and Chief Medical Officer, Eikon Therapeutics
Elena Beltrami, Investment Manager, Biotech Venture Advisors
Sara Benedetti, Group Leader, Assistant Professor in Gene Therapy, University College London
Stefano Benvenuti, Head of Public Affairs and Market Access, Fondazione Telethon
Katja Berg, Global Value and Access Strategy, BBU, AstraZeneca
Niklas Beschorner, Head of R&D, PROVIREX Genome Editing Therapies GmbH
Gaurav Bhavsar, Technical Director, Gene Therapy Vector Facility (GTVF), King's College London
Katie Binley, Chief Scientific Officer, ikarovec
Anne Black, QA Specialist Pharmacist, NHS Specialist Pharmacy Service
Alex Blyth, Founder & CEO, Lift Biosciences Ltd
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Lutz Bonacker, Former Senior Vice President and General Manager, Csl behring
Pedro Borga, Associate Director, Market Access and Pricing, Amicus Therapeutics
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Jonathan Bracey, Founder, MVA Society
Hugh JM Brady, Professor of Immunology, Imperial College London
John Bridgeman, CSO, Immunokey
Simon Briggs, Director, Advanced Analytics, Orchard therapeutics
Leigh Brody, Investment Manager, AlbionVC
Adam Brown, Co-founder and CTO, SynGenSys & Associate Professor of Biopharmaceutical Engineering, The University of Sheffield
Ross Bunyan, External Manufacturing Lead, Resolution Therapeutics
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Cherith Campbell-Bell, Director of Clinical Development, Rinri Therapeutics
Amanda Jayne Carr, Associate Professor, Institute of Ophthalomolgy U.C.L.
Manuel Carrondo, Vice-President, iBET: Instituto de Biologia Experimental e Tecnológica
Paul Carter, Senior Director, MSAT, Quell Therapeutics
Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, AstraZeneca
Prasun Chakraborty, CEO and Founder, Genevation LTD
Carolyn Chan, Senior Specialist Clinical Trials (ATIMPs) and QA Pharmacist, Great Ormond Street Hospital
Fleur Chandler, Patient Advocate and Health Economist, Duchenne U.K.
Alison Clare, Senior Research Associate, University of Bristol
Angela Columbano, Head Business Development and Partnership, Genethon
Jean-Philippe Combal, Co-Founder & Chief Executive Officer, Vivet Therapeutics
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Randolph Corteling, Chief Scientific Officer, ReNeuron
John Counsell, Associate Professor, UCL
Matthieu Coutet, Partner, Sofinnova Partners
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Salmaan Dalvi, Chief Executive Officer, Global Regenerative Medicine Society
Annalucia Darbey, Postdoctoral Research Fellow, University College London
Eric Michael David, Chief Executive Officer of Gene Therapy, BridgeBio
Lindsay Davies, CSO, NextCell Pharma
Maike de la Roche, Senior Group Leader, The Cancer Research UK Cambridge Institute (CRUK-CI)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Victor Dillard, VP, Strategy & Operations, Resolution Therapeutics
Brett Doble, Director HEOR, Australia/Canada/Europe (ACE), HEOR Center of Excellence, Kite, a Gilead Company
Fabien Dorange, Director Analytical Sciences, SparingVision
Marcus Droege, Chief Commercial Officer, MUVON Therapeutics
Beatriz Duran, Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Joseph Egan, Research Associate, Teesside University
Jiri Eitler, Group Leader - NK Cell Therapy, Dresden University of Technology
Tim Farries, Independent Consultant Cell & Gene Therapies, Independent
Jay Feinberg, President, World Marrow Donor Association
Paulo Fernandes, Senior Director, Technical Operations, Spur Therapeutics
Jonathan Fisher, Group Leader – Innate Immune Engineering Laboratory, University College London
Katherine Forsey, Chief Research Officer, Charcot Marie Tooth Association
Miguel Forte, CEO, Kiji Tx
Daniel Fowler, Research Fellow, UCL
George Frodsham, Founder & CEO, MediSieve Limited
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Holly Garlick, Head of GMP, Gene Therapy Innovation & Manufacturing Centre, University of Sheffield
Bobby Gaspar, Chief Executive Officer, Orchard Therapeutics
Bernd Giebel, Professor, University Hospital Essen
Paul Gissen, Clinical Professor of Paediatric Metabolic Medicine, UCL Great Ormond Street Institute of Child Health
Janet Glassford, Expert Quality Assessor, Biologicals Unit, Medicines & Healthcare products Regulatory Agency
Josie Godfrey, Independent Market Access and Rare Disease Adviser, Independent Rare Disease Expert
Wim Goettsch, Special Advisor HTA & Professor for HTA of Pharmaceuticals, Zorginstituut
Roberto Gramignoli, Associate Professor, Karolinska Institutet
Uta Griesenbach, Professor of Molecular Medicine, Imperial College London
Brad Groves, Director, NICE Advice, NICE
Nagy Habib, Professor of Surgery, Imperial College London
Rachel Haines, VP, Clinical Development and Operations, Rinri Therapeutics
Eric Halioua, President & Chief Executive Officer, PDC*line pharma SA
Brian Harrison, Director, Hitech Health
Luke Henry, Chief Business Officer, Quell Therapeutics
Laura Herbst, Group Manager, Fraunhofer-Institute for Production Technology
Victor Hernandez, CSO, Axovia therapeutics
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Ulf Holmgren, Global Pricing and Market Access Director, Astrazeneca
Lilian Hook, Director of Cell, Aphaeresis and Gene Therapies, NHS Blood and Transplant
Patrick Hopkinson, Independent HTA Expert, Independent HTA Expert
Melita Irving, Group Leader, University of lausanne
David James, Professor of Bioprocess Engineering, University of Sheffield
John James OBE, Chief Executive, Sickle Cell Society UK
Sheba Jarvis, Post CCT Post Doctoral Fellow, Imperial College London
Mark Jarvis, Director of Advanced Therapies, Newcastle upon Tyne Hospitals NHS Foundation Trust
Pia Johansson, Director, Cell and Gene Therapy Core, Lund University
Natalie Johnston, Principal, 4BIO CAPITAL
Margareth Jorvid, Board Member, Elicera Therapeutics
Manel Juan, Head of Immunology Service, Hospital Clínic de Barcelona
Tom Kamperman, Founder & CTO, IamFluidics BV
Sophia Karagiannis, Professor of Translational Cancer Immunology and Immunotherapy, King's College London
Claire Kerridge, Head of Gene Therapy, MHRA
Abdullah Khan, Radcliffe Department of Medicine Principal Investigator, MRC WIMM Research Fellow, University of Oxford
Rahul Khetan, Venture Associate, UCB Ventures
Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics
Sven Kili, Partner, Saisei Ventures
Kerstin Kinkelin, Innovation Lead, Bristol BioDesign Institute, University of Bristol
Janine Kirby, Professor, University of Sheffield
Evangelia Kokalaki, Director, Immunobiology, Autolus Therapeutics
Anna Koptina, Head Of Regulatory Affairs, Mendus
Kat Kozyrytska, Founder, Cell Therapy Manufacturability Program
Mathias Kroll, Chief Business Officer, Cynata Therapeutics Ltd
Sandeep Kumar, Head of Advanced Therapy Production, Guy's and St Thomas' NHS Foundation Trust
Dinesh Kundu, CEO, East Ocyon Bio Pvt. Ltd.
David Kuntin, Chief Executive Officer, Mesenbio
Michael Kyriakides, Principal, Syncona Ltd
Nico Lachmann, Professor, Hannover Medical School
Holger Laux, Director of Genetic Medicine, CSL Behring
Inês Leal Reis, Co-founder, Regenera
Roger Legtenberg, Co-Founder, Partners4Patients Foundation
Giulia Leonetti, Policy Officer, European Commission
Michelle Levene, Managing Director, 161 Consulting Ltd
James Levine, President, Fondation Ipsen
Weiwei Li, Highly Specialist Clinical Trials Pharmacist (HaemOnc), Guy's and St Thomas NHS Foundation Trust
Luke Lindsay-Hill, Head of Cell Therapy, Biotherapeutics Advanced Therapies, MHRA
Rosie Lindup, Senior Policy and Public Affairs Manager, BioIndustry Association (BIA)
Patricia Longo, CMC Sr. Staff Scientist, Regeneron
Mark Lowdell, CSO, INmuneBio
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
John Maher, CSO, Leucid Bio
Heather Main, Co-Founder, HOYA consulting
Harris Makatsoris, Professor of Manufacturing, King's College London
Alberto Malerba, Lecturer in Gene Therapy, Royal Holloway University of London
Salah Mansour, Associate Professor, iNKT Cell Therapy, University of Southampton
Athanasios (Sakis) Mantalaris, Professor, Trinity College Dublin
Marcello Maresca, Senior Director - Genome Engineering, AstraZeneca
Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics
Julius Mathews, Group Manager, Fraunhofer Institute for Production Technology IPT
Nazia Matto, sATMP scientist, GMP Facility, Tower wing, Guys Hospital
Dave Mentlak, Senior Scientist, Mesenbio
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Aline Miller, Professor, The University of Manchester
Manal Mohammed, Senior Lecturer (Medical Microbiology), University of Westminster
Paolo Morgese, Vice President, Public Affairs, Europe, Alliance for Regenerative Medicine
David Morrow, Senior Scientific Programme Manager-ATMP/Vaccines, EATRIS
Sophie Mountcastle-Hughes, Programme Manager, Medical Research Council
Noor Mujahid, Head of Vector Process Development, NHS Centre for Cell Gene and Tissue Therapeutics
Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Alexander Natz, Secretary General, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Darren Nesbeth, Associate Professor, University College London
Katy Newton, Chief Scientific Officer, MFX
Joanne Ng, Professor of Genetic Therapy, UCL Institute of Neurology
Roberto Nitsch, Director, AstraZeneca
Hugh O'Brien, CTO, Lir Therapeutics
Daniel O'Connor, Director, Regulatory Policy & Early Access, ABPI
Raphael Ognar, President & CEO, NKILT Therapeutics Inc.
Matias Olsen, Senior Manager, Public Affairs & Policy, EUCOPE - European Confederation of Pharmaceutical Entrepreneurs
Dominic O'Regan, Business Development Consultant & Investor, New Mosaic
Andrew Palfreeman, Associate Director, R&D Lab Core and Operations, Quell Therapeutics
George Pamenter, Researcher, UCL
Kerstin Papenfuss, Director Pharma, Deep Science Ventures
Efstratia Papoutselou, Patient and Public Involvement Lead, Rinri Therapeutics
Adam Parnaby, Lead, Global Policy & Access, BMS
Kathryn Parsley, VP, Regulatory Affairs, Complement Therapeutics
Hamza Patel, Lead Advanced Therapies (Cell & Gene) Specialist Clinical Trial Pharmacist, Great Ormond Street Hospital for Children
Tanya Patel, Senior Manager CTSM, Biontech
Dilip Patel, SVP, Access & Market Development, Autolus
Tom Payne, Chief Operating Officer, Laverock Therapeutics
David Peritt, Chief Scientific Officer, Lupagen
Ana Plata, Head of Global Access, Respiratory & Immunology, Astrazeneca
Riccardo Privolizzi, Senior Research Fellow and Associate Lecturer, University College London
Juliette Pulman, Research Fellow, INSERM
Monica Raimo, Director of Product and Process Development, Glycostem Therapeutics
Lior Raviv, CTO, Pluri
Nicola Redfern, Director, NJ Redfern Ltd.
Vik Reebye, Head of Academic Partnership, MiNA Therapeutics Ltd
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Andrew Roddam, Chief Business Development Officer, EveryONE Medicines
Ali Roghanian, Associate Prof in Cancer Immunotherapy, University of Southampton
Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET
Alex Ross, Head of NHS Cord Bank, NHS Blood and Transplant
Jeroen Rovers, Chief Medical Officer, Mendus
Sean Russell, Head of Regulatory Affairs, Telethon Foundation
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Arthur Sagoskin, Chief Executive Officer & Co-Founder, Mygogenesis
Jorge Salazar, Head of Process Development, INmuneBio
Moin Saleem, Founder and Chief Scientific Advisor, Purespring Therapeutics
Avencia Sánchez-Mejías García, CEO & Co-founder, Integra Therapeutics
Dominic Schmidt, General Partner, Advent Life Sciences
Gerty Schreibelt, Assistant Professor / Immunologist, Radboud University Medical Centre
Sujith Sebastian, Viral Vector Hub Manager, Clinical Biotechnology Centre, NHSBT
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Lior Shaltiel, Chief Executive Officer, NurExone Biologic
Chris Shanks, Content Director, Terrapinn Holdings Ltd
Chrysanthi Sitmalidou, Scientist II, Orchard therapeutics
Owen Smith, Partner, 4BIO CAPITAL
Sarah Snykers, Head of Operations, Legend Biotech
Johannes Solzin, Laboratory Head, Analytical Development, ATMPs, Boehringer Ingelheim
Oliver Spadiut, Head of the Research Area Biochemical Engineering, TU Wien
Dame Molly Stevens, John Black Professor of Bionanoscience, University of Oxford
Nicola Stoner, Consultant Pharmacist - Cancer & ATMPs, Oxford University Hospitals NHS Foundation Trust
Siddharth Subramaniam, Senior Policy and Public Affairs Executive, BIA
Stephen Sullivan, Director, Lindville Bio
Mathias Svahn, Chief Executive Officer, NextCell Pharma
Marina Tarunina, Research Director, Plasticell
Benjamin Taylor, Senior Director, Cell Therapy Biotechnologies, AstraZeneca
Urvi Thacker, Associate Director, MSAT, Quell Therapeutics
Panteli Theocharous, Chief Therapeutics Officer and Head of Medical and Scientific Affairs, Stratus Therapeutics
Stefanos Theoharis, Chief Executive Officer, OneChain Immunotherapeutics
Samantha Thomas, Head of Research, ReNeuron
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Olivier Tramis, Senior Research Scientist, University of Strasbourg
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Marco Traub, Chief Executive Officer, Tesct—Society
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Giandomenico Turchiano, Associate Director, Cell & Gene therapy Safety, AstraZeneca
David Uguen, SVP, Head of Regulatory Affairs, Orchard therapeutics
Sheela Upadhyaya, Life Science Advisor in Rare Diseases & Special Advisor, Openflex Ltd
Hiro Usuda, Scouting & Transaction Lead, Business Development, Astellas
Renaud Vaillant, CEO & co-Founder, Alaya.bio
Sonia Valero, Head Of Clinical Operations - Patient Advocacy Leader, Vivet Therapeutics
Joshi Venugopal, General Manager and Head of Europe, Novartis Gene Therapies
Raul Villamarin Rodriguez, Vice President, Woxsen University
Ketki Vispute, Associate Director, MSAT, Autolus
Valentin von Werz, PhD Researcher, TU Wien
Simon Waddington, Professor of Gene Therapy, UCL
Arsalan Wafi, Academic Clinical Lecturer, King´s College London
Alain Wagner, Director of Research, CNRS
Simon Walker, Head of MSAT, Gene Therapy Vector Facility, Kings College London
Piers Walser, Lead Development Scientist, Clinical Biotechnology Centre, NHSBT
Emily Warner, VP, Technical Operations, ikarovec
Ben Weil, Chief Operating Officer & Chief Manufacturing Officer, INmuneBio
Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Chris Williams, Chief Business Officer, Autolus
Shao-An Xue, Professor, Zhengzhou University of Technology
Ilya Yasny, Partner, LanceBio Ventures
Nan Zhang, Chief, Cell Therapy Manufacturing Section, Center for Cellular Engineering, National Institutes of Health
Federica Zinghirino, Postdoctoral Research Fellow, UCL
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events